Fig. 4: Inosine monophosphate treatment stimulates GMP cell proliferation and Gr-1+ granulocyte production.

a Total cell number of after 3-day treatment of inosine monophosphate or guanosine triphosphate at different concentrations, n = 6–12. b Number of LSK cells after 3-day treatment of inosine monophosphate or guanosine triphosphate at different concentrations, n = 6–9. c, d The frequency and cell number of GMP after 3-day treatment of inosine monophosphate or guanosine triphosphate at different concentrations, n = 5–12. e Quantification of BrdU-incorporating lineage^−/low or GMP cells after 3-day treatment of IMP analyzed by FACS, n = 6. f FACS analysis of Gr-1⁺ granulocyte production after five days of IMP treatment. n = 6. g Quantification of cKit expression on lineage^−/lowSca-1⁻ cells membrane after transient exposure of IMP for 5, 15 and 30 min, respectively, n = 6. h Representative analysis of cKit expression in lineage^−/low cells. i, j Western blot of total S6 and phosphorylation of S6 in lineage^−/low cells after exposure of IMP for 15 and 30 min, respectively. β-actin was used as loading control, n = 9. k–n Quantification of FACS data of pS6-positive cells in lineage^−/low and GMP cells, respectively, n = 5–6. Representative FACS analysis of pS6 activation in lineage^−/low and GMP cells (k) and (m). One-way ANOVA with Dunnett was used to compare groups against control.